Mesuximide

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)^[1] and Celontin (United States).^[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.^[3]

Mesuximide

Clinical data
Trade names	Celontin
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a682028
Routes of administration	By mouth (capsules)
ATC code	N03AD03 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Metabolism	Hepatic (demethylation and glucuronidation)
Metabolites	N-desmethylmethosuximide
Elimination half-life	1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite)
Excretion	Urine
Identifiers
IUPAC name (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
CAS Number	77-41-8 Y
PubChem CID	6476
IUPHAR/BPS	7228
DrugBank	DB05246 N
ChemSpider	6231 Y
UNII	0G76K8X6C0
KEGG	D00404 Y
ChEMBL	ChEMBL697 Y
CompTox Dashboard (EPA)	DTXSID5023293
ECHA InfoCard	100.000.934
Chemical and physical data
Formula	C12H13NO2
Molar mass	203.241 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES O=C2N(C(=O)CC2(c1ccccc1)C)C
InChI InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3 Y Key:AJXPJJZHWIXJCJ-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Medical use

The medical use is indicated for the control of absence seizures that are refractory to other drugs.^[2]